In their interim futility analysis by the same independent DMC...

In their interim futility analysis by the same independent DMC announced on 10 April 2017, they determined that the trial has met the pre-specified primary endpoint and have recommended the trial to be continued.

IMHO, I read it correctly it means the 270 patients were reacting positively and showing statiscally significance improvements - note here this is half of the population involved in the trial. Otherwise, the trial would have been terminated back then.

So the likelihood of a successful trial in demonstrating primaryendpoint of reduction in heart failure-related hospital admissions, and in the key secondary endpointof reduction in cardiac deaths is high.

Disclaimer - this is not a recommendation of buy, sell or hold. Please do not rely on the above opinions. It doesn't take into account your personal circumstances. Please consult your financial adviser and do your own research.